G protein-coupled receptor

CB2 receptor

Cannabinoid receptor 2

The CB2 receptor was cloned from the human leukaemia cell line HL60. In that first study it was found not in the brain but in macrophages of the spleen.1

Like CB1 it inhibits the formation of cyclic AMP, and THC binds both about equally well. Unlike CB1 it did not act on calcium and potassium channels, and the CB1 blocker rimonabant (SR141716A) blocks it poorly.2

CB2 receptors have a more restricted distribution than CB1 receptors. They are found in a number of immune cells and in a few neurones.3 The receptor was first considered the peripheral cannabinoid receptor, based on its abundant expression in the immune system and its presumed absence from the central nervous system. It is now well accepted that it is expressed in brain microglia during neuroinflammation, but the extent of its expression in neurons has remained controversial, with claims ranging from complete absence to widespread expression. The authors of a review recommend cautious interpretation of the data for and against CB2 in neurons.4 In the rat, CB2 receptor messenger RNA was found in the cerebellum, cortex and brainstem, and the brainstem held 1.5 percent of the amount found in the spleen. Immunoreactivity was found in neurons of the dorsal motor nucleus of the vagus, the nucleus ambiguus and the spinal trigeminal nucleus, but not in glial cells or blood vessels. These brainstem receptors were activated by the endocannabinoid 2-arachidonoylglycerol.5 Another group reported CB2 messenger RNA in cerebellar neurons of wild-type but not of CB2 knockout mice. Transcripts in the brain were at levels much lower than those of CB1. The authors suggest that brain CB2 receptors may be involved in depression and drug abuse.6

The first mice with a targeted mutation in the CB2 gene appeared healthy, were fertile and cared for their offspring, and the immune cell populations were not different. Binding of a cannabinoid agonist was absent in their spleen, while binding in the central nervous system was unchanged. THC inhibited the activation of helper T cells through macrophages from normal mice but not from the knockouts, so this effect is mediated by CB2, while the central nervous system effects of cannabinoids were not altered.7

A review suggests that endocannabinoid signalling through CB2 receptors may be part of a protective system. Inflammation and tissue injury trigger rapid rises in local endocannabinoid levels. Changes in endocannabinoid levels or in CB2 expression have been reported in almost all diseases that affect humans. CB2 activation in general mediates immunosuppressive effects that limit inflammation, but in some disease states it may enhance or even trigger tissue damage.8

Sources (8)
  1. Munro et al. 1993Munro S, Thomas KL, Abu-Shaar M (1993) Molecular characterization of a peripheral receptor for cannabinoids Nature
  2. Felder et al. 1995Felder CC, Joyce KE, Briley EM, et al. (1995) Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors Mol Pharmacol
  3. Mackie 2008Mackie K (2008) Cannabinoid receptors: where they are and what they do J Neuroendocrinol
  4. Atwood et al. 2010Atwood BK, Mackie K (2010) CB2: a cannabinoid receptor with an identity crisis Br J Pharmacol
  5. Van Sickle et al. 2005Van Sickle MD, Duncan M, Kingsley PJ, et al. (2005) Identification and functional characterization of brainstem cannabinoid CB2 receptors Science
  6. Onaivi et al. 2006Onaivi ES, Ishiguro H, Gong JP, et al. (2006) Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain Ann N Y Acad Sci
  7. Buckley et al. 2000Buckley NE, McCoy KL, Mezey E, et al. (2000) Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor Eur J Pharmacol
  8. Pacher et al. 2011Pacher P, Mechoulam R (2011) Is lipid signaling through cannabinoid 2 receptors part of a protective system? Prog Lipid Res

Binding affinity (Kᵢ)

10 substances, 15 displayed values. Strongest first within each organism. The bar is pKᵢ on a log scale. Open a row to see the assay and every report behind the value.

Human

10 measurements

Mouse

2 measurements

Rat

2 measurements

Unspecified

1 measurement
  • JWH-018Agonistsource not traced2.9 nMBanister et al. 2015
    Assay
    literature binding value as compiled in Table S8, original assay of Aung 2000 (Drug Alcohol Depend 60:133)
    Shown value from
    Banister et al. 2015, Table S8 (Supporting Information)

Functional potency (EC₅₀)

9 substances, 9 displayed values. Strongest first within each organism. Emax is shown where the paper reports it. Efficacy depends on the assay and its reference agonist.

Human

9 measurements
  • HU-210Agonist0.50 nMRyberg et al. 2007
    Assay
    HEK293 membranes expressing human CB2, [35S]GTPgammaS binding
    Shown value from
    Ryberg et al. 2007, Table 1
    Error
    ± 0.10 SEM, n = 5
    Emax
    99.0 ± 6.0%
  • CP 55,940Agonistdepends on assay36 nMScott et al. 2019 · 2 reports
    Assay
    Membranes of HEK293T cells expressing human CB2; [35S]GTPγS binding
    Shown value from
    Scott et al. 2019, Table 1
    Range
    0.30–36 nM in 2 reports
    Error
    ± 26 SEM, n = 3

    Values depend on the assay, species or conditions, and each is valid only for its own. 5 reports in all, 0.30–560 nM.

    Sources and values behind the range, same assay family
    ReportValueWhere
    Scott et al. 201936 nMTable 1
    Ryberg et al. 20070.30 nMTable 1
  • Cannabidiol (CBD)Agonist58 nMZagzoog et al. 2020
    Assay
    PathHunter CHO cells stably expressing human receptor; beta-arrestin2 recruitment for 90 min; variable-slope four-parameter fit; independent experiments in triplicate
    Shown value from
    Zagzoog et al. 2020, Table 3
    Emax
    23.0 ± 2.8%
  • WIN 55,212-2Agonist62 nMBanister et al. 2015
    Assay
    mouse AtT-20 cells stably expressing human CB2, FLIPR membrane-potential/GIRK assay
    Shown value from
    Banister et al. 2015, Table 1
  • Cannabigerol (CBG)Agonistdepends on assay130 nMZagzoog et al. 2020
    Assay
    HitHunter CHO cells stably expressing human receptor; inhibition of forskolin-stimulated cAMP for 90 min; variable-slope four-parameter fit; independent experiments in triplicate
    Shown value from
    Zagzoog et al. 2020, Table 2
    Emax
    39.0 ± 11.0%

    Values depend on the assay, species or conditions, and each is valid only for its own. 2 reports in all, 130–1158 nM.

  • JWH-018Agonist133 nMBanister et al. 2015
    Assay
    mouse AtT-20 cells stably expressing human CB2, FLIPR membrane-potential/GIRK assay
    Shown value from
    Banister et al. 2015, Table 1
    Emax
    95.0 ± 5.0%
  • Cannabinol (CBN)Agonist289 nMHusni et al. 2014
    Assay
    HEK293 cells expressing human CB2 membranes; [35S]GTPγS functional assay
    Shown value from
    Husni et al. 2014, Table 1
  • Δ⁸-THC (Tetrahydrocannabinol)Agonist524 nMHusni et al. 2014
    Assay
    HEK293 cells expressing human CB2 membranes; [35S]GTPγS functional assay
    Shown value from
    Husni et al. 2014, Table 1
  • Δ⁹-THC (Tetrahydrocannabinol)Agonistother reports differ1157 nMBanister et al. 2015
    Assay
    mouse AtT-20 cells stably expressing human CB2, FLIPR membrane-potential/GIRK assay
    Shown value from
    Banister et al. 2015, Table 1
    Emax
    13.0%

    This is the best-supported value. Other reports differ. 5 reports in all, 0.40–1157 nM.

Also reported to act here

Substances reported to act here, without a displayed value.

Values are published numbers in nM per organism. Different assays, species and receptor preparations are not directly interchangeable, and a value does not establish clinical potency or safety.